IMUX

MKT CAP:$87M

Immunic, Inc.

Market Cap

$87M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.92+$0.34 (+57.51%)

Apr 23, 2026

Company Details

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Ph...

CEO

Daniel Vitt

IPO Date

Apr 17, 2014

Website

www.immunic-therapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$97M

EPS (Diluted)

-$0.62

Free Cash Flow

-$86M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Feb 26, 2026

$0EPS -$0.62

Q4 2025

Feb 26, 2026

$0EPS -$0.04

Q3 2025

Nov 13, 2025

$0EPS -$0.13

Q2 2025

Aug 7, 2025

$0EPS -$0.20

Q1 2025

May 15, 2025

$0EPS -$0.25

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$21M
Q2 22	$0	$0	-$21M
Q3 22	$0	$0	-$20M
Q4 22	$0	$0	-$57M
Q1 23	$0	$0	-$27M
Q2 23	$0	$0	-$25M
Q3 23	$0	$0	-$24M
Q4 23	$0	-$23.0K	-$23M
Q1 24	$0	-$26.0K	-$24M
Q2 24	$0	-$31.0K	-$23M
Q3 24	$0	$0	-$26M
Q4 24	$0	-$35.0K	-$26M
Q1 25	$0	$0	-$27M
Q2 25	$0	$0	-$27M
Q3 25	$0	$0	-$26M
Q4 25	$0	-$42.0K	-$23M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$21M	-$21M
Q2 22	-$16M	-$16M
Q3 22	-$14M	-$14M
Q4 22	-$15M	-$15M
Q1 23	-$20M	-$20M
Q2 23	-$20M	-$20M
Q3 23	-$17M	-$17M
Q4 23	-$14M	-$14M
Q1 24	-$24M	-$24M
Q2 24	-$17M	-$17M
Q3 24	-$21M	-$21M
Q4 24	-$23M	-$23M
Q1 25	-$22M	-$22M
Q2 25	-$25M	-$25M
Q3 25	-$20M	-$20M
Q4 25	-$19M	-$19M

Capital Expenditures

Quarter	CapEx
Q1 22	$12.0K
Q2 22	$28.0K
Q3 22	$73.0K
Q4 22	$1.0K
Q1 23	$104.0K
Q2 23	$21.0K
Q3 23	$44.0K
Q4 23	$165.0K
Q1 24	$31.0K
Q2 24	$180.0K
Q3 24	$50.0K
Q4 24	$3.0K
Q1 25	$47.0K
Q2 25	$36.0K
Q3 25	$67.0K
Q4 25	$11.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-33.8%
Q2 22	—	+7.5%
Q3 22	—	+9.4%
Q4 22	—	+163.9%
Q1 23	—	+27.1%
Q2 23	—	+21.4%
Q3 23	—	+17.2%
Q4 23	—	-59.2%
Q1 24	—	-12.4%
Q2 24	—	-8.8%
Q3 24	—	+9.1%
Q4 24	—	+9.6%
Q1 25	—	+12.3%
Q2 25	—	+18.7%
Q3 25	—	+1.0%
Q4 25	—	-9.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$2M	—
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$3M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$4M	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$17M	$4M	—
Q2 22	$17M	$4M	—
Q3 22	$17M	$4M	—
Q4 22	$21M	$4M	—
Q1 23	$23M	$4M	—
Q2 23	$21M	$4M	—
Q3 23	$20M	$4M	—
Q4 23	$19M	$4M	—
Q1 24	$19M	$5M	—
Q2 24	$18M	$4M	—
Q3 24	$21M	$4M	—
Q4 24	$22M	—	$4M
Q1 25	$22M	$5M	—
Q2 25	$21M	$6M	—
Q3 25	$20M	—	$6M
Q4 25	$19M	$4M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$96M	$0	$96M
Q2 22	$88M	$0	$88M
Q3 22	$73M	$0	$73M
Q4 22	$107M	$10M	$116M
Q1 23	$93M	$4M	$97M
Q2 23	$77M	$0	$77M
Q3 23	$60M	$0	$60M
Q4 23	$47M	$0	$47M
Q1 24	$97M	$0	$97M
Q2 24	$80M	$0	$80M
Q3 24	$59M	$0	$59M
Q4 24	$36M	$0	$36M
Q1 25	$14M	$0	$14M
Q2 25	$55M	$0	$55M
Q3 25	$35M	$0	$35M
Q4 25	$15M	$0	$15M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	28M	+11.1%	+32.8%
Q2 22	30M	+7.5%	+39.1%
Q3 22	31M	+1.0%	+20.7%
Q4 22	32M	+4.1%	+25.7%
Q1 23	44M	+37.2%	+55.2%
Q2 23	44M	+1.8%	+46.9%
Q3 23	45M	+0.3%	+45.8%
Q4 23	45M	+0.1%	+40.3%
Q1 24	97M	+118.0%	+122.8%
Q2 24	101M	+4.1%	+127.9%
Q3 24	101M	0.0%	+127.2%
Q4 24	90M	-11.0%	+102.0%
Q1 25	101M	+12.4%	+4.2%
Q2 25	132M	+30.4%	+30.5%
Q3 25	194M	+46.7%	+91.5%
Q4 25	1.56B	+702.9%	+1627.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	55
Q2 22	$0	55
Q3 22	$0	55
Q4 22	$0	66
Q1 23	$0	66
Q2 23	$0	66
Q3 23	$0	66
Q4 23	$0	77
Q1 24	$0	77
Q2 24	$0	77
Q3 24	$0	77
Q4 24	$0	91
Q1 25	$0	91
Q2 25	$0	91
Q3 25	$0	91
Q4 25	$0	92

Revenue / Employee